Europe — EMA
Neranol (Tapentadol)
GNH USA supplies Neranol (Tapentadol), an opioid analgesic for moderate to severe acute pain and chronic pain. Request a quote for global supply today.
Request sourcing
What is Tapentadol?
Tapentadol, the active ingredient in Neranol, is an opioid analgesic presented as a tablet oral for oral use. It treats moderate to severe acute pain and chronic pain in adults.
GNH USA supplies Neranol as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Tapentadol used for?
Tapentadol is an opioid analgesic indicated for pain management.
- Moderate to severe acute pain: provides analgesia for short‑term postoperative or injury‑related pain. - Chronic musculoskeletal pain: helps control persistent pain when other treatments are insufficient. - Cancer‑related pain: used as part of a multimodal regimen for severe cancer pain.
What are the side effects of Tapentadol?
Tapentadol may cause a range of adverse reactions, which are grouped by frequency.
Common Side Effects: - Nausea - Constipation - Dizziness - Somnolence - Headache - Vomiting
Serious or Rare Side Effects: - Respiratory depression - Seizures - Severe hypotension - Serotonin syndrome - Addiction or physical dependence - Adrenal insufficiency
What precautions apply to Tapentadol?
When using Neranol, several safety considerations should be observed.
- Assess renal and hepatic function: adjust use in patients with impairment. - Avoid in patients with significant respiratory depression: monitor breathing closely. - Use cautiously with other CNS depressants: increased risk of sedation and respiratory effects. - Monitor for signs of abuse or dependence: provide patient education and regular assessment. - Store at ambient temperature: keep in the original pack, protect from moisture.
What does Tapentadol interact with?
Tapentadol can interact with other medicines, requiring attention to avoid harmful effects.
Major Interactions (Avoid): - Concomitant use with other opioids: heightened risk of respiratory depression. - Monoamine oxidase inhibitors (MAOIs): potential for hypertensive crisis. - Serotonergic agents (e.g., SSRIs, SNRIs): increased risk of serotonin syndrome.
Moderate Interactions (Monitor Closely): - Benzodiazepines: additive sedation and respiratory depression. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise tapentadol plasma concentrations. - Alcohol: combined central nervous system depression.



